Thanks to the support of our valued clients and esteemed colleagues, SNBL Group celebrated its 60th anniversary on Saturday, September 16th, 2017. Since being founded in 1957 in Kagoshima, Japan, SNBL has gone on to expand around the world, and from preclinical testing all the way to innovative cancer treatment at our proton beam therapy center and resort. For the past 60 years we have been committed to freeing patients from suffering, by supporting drug development and improving medical technology. We hope to continue this important work over the next 6 decades, and to cement our place as Japan’s oldest and largest pre-clinical CRO.
We appreciate your continued support and hope to work with you as we continue to strive forward.
On September 13th, SNBL Japan received the 2017 Award for the Promotion of Women in Business, an award presented by Kagoshima Prefecture as part of the Plan for the Equality of Men and Women.
The award is presented to companies with a high number of women managers and employees, a low turnover rate for women, childcare leave for men, and good work-life balance. SNBL Japan was 1 of 3 companies to receive this award. SNBL Japan especially stood out in the turnover rate for women at 5.9%, an improvement of 5.2 points over the past 10 years. Parental leave and return to work after childbirth are considered to be an ordinary part of the company climate at SNBL.
In August, one of our DART scientists presented a poster at the 57th Japanese Teratology Society Meeting, entitled “Investigation of Learning and Memory in Cynomolgus Monkeys Using a Finger Maze.” She received a Selected Poster Presentation Award from the Japanese Teratology Society Meeting for this research.
If you would like to learn more about our DART capabilities, including the finger maze test, please contact us at email@example.com.
There was a magnitude 5 earthquake in Kagoshima at 11:56 on July 11, 2017, in Kagoshima. There was no damage to any of our Kagoshima facilities.
The FDA requires data from single and repeated-dose general toxicity and carcinogenicity preclinical studies that begin after December 17, 2016 to be submitted electronically in Standard for Exchange of Nonclinical Data (SEND) format.
SNBL uses our custom data collection system and Pinnacle 21 Enterprise to produce datasets for our preclinical studies. We completed validation of our SEND process earlier this year and we are ready to deliver SEND data packages.
Please email us to discuss how we can partner with you on SEND solutions for your preclinical needs.